In the United States, 1 in 3 people are experiencing chronic pathological complications from glucose dysregulation. Praetego is a start-up pharmaceutical company in Durham, NC, focused on protecting these patients. Praetego’s novel small molecules (the Amadorins) offer the possibility of systemic protection from glucose damage. Treatment with an Amadorin could radically improve the health of diabetic and pre-diabetic patients.

Recently, the FDA contacted Praetego to repurpose our lead Amadorin, PimoxIV (IND#143,097), for COVID-19 renal protection. COVID-19 mortality data is showing marked correlation with pre-existing and emergent glucose dysregulation. PimoxIV is an IV infusion for hospitalized patients to protect kidneys and improve clinical outcomes. The active ingredient in PimoxIV has extensive clinical and nonclinical data supporting kidney preservation and a benign safety profile. No other COVID-19 clinical program appears to focus on kidney preservation.

We are raising a...
In the United States, 1 in 3 people are experiencing chronic pathological complications from glucose dysregulation. Praetego is a start-up pharmaceutical company in Durham, NC, focused on protecting these patients. Praetego’s novel small molecules (the Amadorins) offer the possibility of systemic protection from glucose damage. Treatment with an Amadorin could radically improve the health of diabetic and pre-diabetic patients.

Recently, the FDA contacted Praetego to repurpose our lead Amadorin, PimoxIV (IND#143,097), for COVID-19 renal protection. COVID-19 mortality data is showing marked correlation with pre-existing and emergent glucose dysregulation. PimoxIV is an IV infusion for hospitalized patients to protect kidneys and improve clinical outcomes. The active ingredient in PimoxIV has extensive clinical and nonclinical data supporting kidney preservation and a benign safety profile. No other COVID-19 clinical program appears to focus on kidney preservation.

We are raising a seed round of $2.5m to accelerate the clinical proof of concept program with PimoxIV for renal protection in COVID-19 patients while pursuing non-dilutive funding. Praetego is actively communicating with BARDA to fund this program.

PimoxIV is the first Amadorin in our pipeline. Preclinical Amadorin development is currently supported by NIH awards. Praetego has substantial patent protection for the Amadorin series (issued and provisional). The management team and Advisory Board are highly qualified to execute our diabetic focused development and commercialization plan.
More information

Employees

Pepper Landson
Admin
Pepper Landson CEO Ms. Landson is an accomplished healthcare executive with 30 years of experience in research and development, much of that time in start-ups.